Rigel Pharmaceuticals Balances Breakout Growth With Caution

Rigel Pharmaceuticals ((RIGL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Rigel Pharmaceuticals’ latest earnings call blended strong commercial momentum with prudent caution. Management highlighted a 60% jump in annual net product sales, record quarterly results, and a doubled cash balance, while also flagging noncash tax benefits, one-time growth tailwinds, and early-stage clinical data risks that temper the headline numbers.

Robust Full-Year Sales Growth Across the Portfolio

Rigel reported 2025 net product sales of $232 million, up $87 million or 60% from 2024, as demand grew across its three-product portfolio. Management credited both underlying prescription strength and portfolio expansion, underscoring that the company’s commercial platform is scaling meaningfully from its 2022 base.

Record Fourth Quarter Underscores Momentum

Fourth quarter 2025 net product sales reached $65.4 million, a 41% year-over-year increase and the strongest quarter in the company’s history. The performance reinforced that Rigel exited the year with solid demand trends, even as management cautioned that some tailwinds were nonrecurring.

Product-Level Strength Led by TAVALISSE

By product, Q4 2025 sales showed broad-based gains: TAVALISSE generated $45.6 million, up 47% year over year, while GAVRETO reached $10.2 million and REZLIDHIA $9.6 million, rising 27% and 29%. These results suggest Rigel is leveraging its sales force efficiently across multiple hematology-oncology brands.

Headline Profitability and a Much Stronger Balance Sheet

Rigel posted full-year 2025 GAAP net income of $367 million versus $17.5 million in 2024 and ended the year with $155 million in cash, cash equivalents, and short-term investments, roughly double prior-year levels. The company emphasized it is now operating profitably while carrying a significantly fortified balance sheet to support future investments.

Early but Encouraging R289 Data in MDS

In its Phase Ib study of R289 in heavily pretreated lower-risk MDS patients, 6 of 18 evaluable patients at doses of at least 500 mg achieved red blood cell transfusion independence for at least eight weeks. Median duration of response was about 23 weeks with onset around two months, and the drug appeared generally well tolerated, with low rates of severe cytopenias or infections.

Regulatory Tailwinds for R289

R289 has secured FDA Fast Track designation and orphan drug status in MDS, which together can streamline development and review while supporting potential market exclusivity. These designations signal regulatory recognition of the unmet need and may enhance the asset’s strategic and commercial value if efficacy is confirmed.

Business Development as a Proven Growth Lever

Management pointed to the in-licensing of REZLIDHIA in 2022 and GAVRETO in 2024 as proof of its ability to bolt on late-stage assets. By layering these products onto its existing commercial infrastructure, Rigel has grown revenue with limited integration friction, reinforcing BD as a central pillar of its growth strategy.

2026 Outlook: Growth with Positive Earnings

Rigel guided 2026 total revenue to $275–$290 million, including $255–$265 million in net product sales and $20–$25 million in contract revenue, and expects to remain profitable while funding clinical trials. At the midpoint, net product sales imply roughly a 35% compound annual growth rate since 2022, signaling confidence in continued expansion.

Noncash Tax Benefit Inflates Reported Earnings

The company stressed that 2025’s $367 million GAAP net income was heavily influenced by a roughly $245.9 million noncash deferred tax benefit from releasing a valuation allowance. While this accounting change boosts reported earnings, it does not reflect cash generation and investors were urged to focus more on operating performance and cash flow.

One-Time Tailwinds Behind Part of 2025 Surge

Management noted that 2025 growth benefited from one-off factors, including improved patient affordability linked to Medicare coverage changes and favorable gross-to-net dynamics. These elements provided a temporary boost, meaning 2025’s 60% sales growth should not be extrapolated as a new baseline trend.

Rising Costs from Clinical and Personnel Investments

Total costs and expenses climbed to $46.6 million in Q4 2025 from $40.9 million a year earlier and to $168.8 million for the full year from $155.1 million. The increase, roughly 14% in the quarter and 9% for the year, was driven mainly by the timing of clinical work and higher personnel-related spending as Rigel builds out capabilities.

R289 Dataset Still Too Small for Firm Conclusions

Despite promising transfusion-independence rates, the Phase Ib R289 dataset remains limited, with 33 patients in dose escalation and 18 evaluable at higher doses. Management underscored that more robust dose-expansion and potential registration data will be needed before the drug’s true benefit and commercial opportunity can be confidently assessed.

Revenue Quality Shaped by Inventory and Discounts

The company indicated that favorable gross-to-net adjustments and lower inventory levels partly offset revenue trends, suggesting some of the uplift reflected pricing and accounting dynamics. Investors were reminded to look through these factors when gauging underlying demand and sustainable revenue growth.

Conservative Guidance After a Breakout Year

Rigel’s 2026 net product sales outlook of $255–$265 million implies healthy but more modest double-digit growth versus the 60% jump in 2025. Management framed this as a deliberate, conservative stance that accounts for the fading of one-time 2025 benefits and the realities of competitive markets.

Navigating Market Access and Competitive Pressures

Executives acknowledged rising challenges in reaching clinicians and contending with a crowded treatment landscape in indications such as ITP and MDS. Sustaining share gains will require targeted commercial execution and differentiation, particularly as new rivals and treatment options emerge.

Reliance on Future Deals to Extend Growth Runway

Rigel’s long-term plan assumes additional late-stage in-licensing or acquisitions that could launch by 2028, building on its BD track record. Management also noted, however, that execution risk around finding, negotiating, and integrating the right assets remains a key variable in the company’s growth story.

Measured Guidance and Clinical Milestones Ahead

Looking ahead, Rigel expects 2026 revenue of $275–$290 million with net product sales of $255–$265 million and contract revenue of $20–$25 million, alongside continued positive net income. The company plans to select a Phase II dose for R289 in the second half of 2026 and aims to report dose-expansion topline data by year-end, positioning the asset for potential next-stage development decisions.

Rigel’s call painted a picture of a company hitting its commercial stride while managing investor expectations with realism. Strong multi-product growth, improved profitability, and a reinforced balance sheet are counterbalanced by accounting boosts, one-time benefits, and clinical and BD execution risks, leaving shareholders with a cautiously optimistic outlook.